Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Vergiss die Indizes - Forge steigt um 40 %, während der S&P & Dow fällt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12A5F | ISIN: CA31447P1009 | Ticker-Symbol: RV41
Frankfurt
25.04.25
08:20 Uhr
4,880 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
FENNEC PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
FENNEC PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,8204,98020:06
4,8004,98020:06

Aktuelle News zur FENNEC PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
26.03.FENNEC PHARMACEUTICALS INC. - 10-K, Annual Report4
FENNEC PHARMACEUTICALS Aktie jetzt für 0€ handeln
11.03.Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2024 Earnings Call Transcript2
11.03.H.C. Wainwright maintains $13 target on Fennec stock3
10.03.FENNEC PHARMACEUTICALS INC. - 8-K, Current Report2
10.03.Fennec Pharmaceuticals Inc Q4 Loss Decreases, Beats Estimates2
10.03.Fennec Pharmaceuticals GAAP EPS of -$0.06, revenue of $7.93M2
10.03.Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update113~ Achieved Full-Year PEDMARK® Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK® Q4 2024 Net Product Sales of $7.9 Million ~ ~ Delivered Q4 2024 EBITDA Loss of $0.6...
► Artikel lesen
07.03.Fennec Pharmaceuticals Inc: Fennec to release 2024 results March 104
06.03.Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 20253
07.02.FENNEC PHARMACEUTICALS INC. - 8-K, Current Report-
07.02.Fennec Pharmaceuticals Inc: Fennec licensee begins selling Pedmarqsi in Germany2
07.02.Stocks in Play: Fennec Pharmaceuticals Inc.7
07.02.Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI In Germany178~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to ~ Norgine Pharmaceuticals'...
► Artikel lesen
20.12.24Fennec's Pedmarqsi gets nod from U.K. regulators1
20.12.24FENNEC PHARMACEUTICALS INC. - 8-K, Current Report-
20.12.24Fennec Pharmaceuticals Inc: Fennec's Pedmarqsi receives recommendation from NICE2
20.12.24Stocks in Play: Fennec Pharmaceuticals Inc.-
20.12.24Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Announces Pedmarqsi Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales162~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and...
► Artikel lesen
19.12.24Fennec Pharmaceuticals partially repays its outstanding convertible debt facility2
19.12.24Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management10
Seite:  Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1